| Product NDC: | 0078-0323 |
| Proprietary Name: | Exelon |
| Non Proprietary Name: | rivastigmine tartrate |
| Active Ingredient(s): | 1.5 mg/1 & nbsp; rivastigmine tartrate |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0078-0323 |
| Labeler Name: | Novartis Pharmaceuticals Corporation |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020823 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20000430 |
| Package NDC: | 0078-0323-08 |
| Package Description: | 500 CAPSULE in 1 BOTTLE (0078-0323-08) |
| NDC Code | 0078-0323-08 |
| Proprietary Name | Exelon |
| Package Description | 500 CAPSULE in 1 BOTTLE (0078-0323-08) |
| Product NDC | 0078-0323 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | rivastigmine tartrate |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 20000430 |
| Marketing Category Name | NDA |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Substance Name | RIVASTIGMINE TARTRATE |
| Strength Number | 1.5 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Cholinesterase Inhibitor [EPC],Cholinesterase Inhibitors [MoA] |